Zhejiang Tailin Bioengineering Co (300813.SZ) Stock Price

Zhejiang Tailin Bioengineering Co., Ltd. generates revenue through the research, development, manufacturing, and sales of pharmaceutical equipment, including microbial detection and control technology system products and organic substance analysis instruments. The company's main products consist of consumables, instruments, and equipment used in sterile drug production and quality control, targeting pharmaceutical manufacturers and laboratories. These products serve applications in medical and health, food safety, disease prevention, biosecurity, inspection and quarantine, biological engineering, laboratory animals, and environmental protection sectors. The firm distributes its products domestically and internationally, with a focus on the Chinese market and overseas markets. The company's revenue streams are derived from the sale of microbial detection and control technology system products, organic substance analysis instruments, and related consumables. Pharmaceutical manufacturers and laboratory facilities are the primary customers purchasing these products for quality assurance and production processes. The application segments include medical and health, food safety, disease prevention, biosecurity, inspection and quarantine, biological engineering, laboratory animals, and environmental protection, which are served through both domestic and international distribution channels. Zhejiang Tailin Bioengineering's business model centers on selling specialized pharmaceutical equipment to industries requiring sterile drug production and quality control. The firm's products are utilized across multiple sectors such as medical and health, food safety, disease prevention, biosecurity, inspection and quarantine, biological engineering, laboratory animals, and environmental protection. Sales occur within the domestic market and overseas markets, with a strong emphasis on the Chinese market and international expansion.